ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Nasal Polyps
Rhinitis
Rhinosinusitis
Chronic Obstructive Pulmonary Disease
Lung Diseases

Asthma trials near Warszawa, Mazowieckie, POL:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 125 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Enrolling
Asthma Attack
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 209 other locations

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

Phase 2

Incyte
Incyte

Warszawa, Poland and 92 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 381 other locations

propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma...

Enrolling
Asthma
Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a
Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Phase 3

Chiesi
Chiesi

Warsaw, Poland and 142 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Active, not recruiting
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Piaseczno, Poland and 362 other locations

expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma...

Enrolling
Asthma
Mild Asthma
Drug: Salbutamol HFA-134a
Drug: Salbutamol HFA-152a

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Jozefow, Poland and 9 other locations

birch pollen-induced allergic rhinoconjunctivitis, with or without asthma, when treated before and during the pollen season.Approximately 69...

Active, not recruiting
Birch Pollen Allergy
Allergic Rhinoconjunctivitis
Drug: STALORAL® Birch 300 IR

Phase 3

Stallergenes Greer
Stallergenes Greer

Warsaw, Poland and 61 other locations

Primary Objective-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smellSecondary Objec...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

Phase 4

Sanofi
Sanofi

Warszawa, Mazowieckie, Poland and 94 other locations

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling
Wheezing Lower Respiratory Illness
Recurrent Wheezing
Drug: OM-85
Drug: Placebo

Phase 2

OM Pharma

Skierniewice, Lodzkie, Poland and 36 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems